Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Private biopharmaceutical firm Xencor and Chugai Pharmaceutical Co, the fifth largest pharmaceutical company in Japan in terms of sales, have formed a license and collaboration agreement to create monoclonal antibodies to be used against a proprietary cancer target.
Subscribe to our email newsletter
Chugai will use Xencor’s XmAb technology on its antibodies against a cancer target. The XmAb technology consists of a suite of engineered antibody Fc domains that can be applied to any antibody to control the recruitment of the immune system’s effector functions and to greatly increase antibody-mediated tumor killing.
Under the terms of the agreement, Xencor will receive technology access and license fees, and is eligible to receive additional license fees, milestones and royalties in the event Chugai advances candidates into development.
“We are excited that Chugai is partnering with us to apply our XmAb technology in its antibody discovery efforts,” said Dr Harry Stylli, president and CEO of Xencor. “The Chugai collaboration furthers our strategy of licensing the XmAb technology to multiple partners for specific targets while retaining rights for the internal development of a portfolio of next-generation antibodies.”